Global agri business major Syngenta Group has reported full-year and fourth-quarter 2025 results, highlighting operational resilience, strong margins, and robust cash flow.

 

Full-year sales rose 2% after adjusting for the Group’s $1 billion strategic reduction in lower-margin grain trading, though reported sales fell 1% to $28.4 billion. The boost came from strong Crop Protection volumes driven by continued product innovation.

 

“EBITDA for the full year rose to $4.4 billion, up 13% year-on-year,” Syngenta said. “This performance was underpinned by a 1.9-percentage-point expansion in the full-year EBITDA margin to 15.4%.”

 

Q4 sales hit $7.6 billion, up 2% year-on-year, with declines in ADAMA and SGC offset by gains in Crop Protection and Seeds. EBITDA fell 16% from last year due to MAP restructuring, higher customer credit provisions in Brazil, and a strong prior-year comparison.

 

Despite global uncertainties, depressed commodity prices, and disrupted trade, Syngenta’s new product launches across all business units drove performance. The company also prioritized artificial intelligence through high-impact “lighthouse” projects, unlocking measurable financial impact.

 

“The disciplined approach is already delivering measurable financial impact and establishing scalable blueprints that will accelerate transformation across the company,” Syngenta said.

 

The Group’s biologicals business achieved double-digit sales growth, supported by a new production facility in Orangeburg, South Carolina, adding to sites in Brazil, Italy, India, and Norway.

 

Syngenta appointed Nelson Jiang as Group CFO, effective March 1, 2026. Jiang brings over 30 years of financial leadership experience and will relocate to Basel. Hengde Qin transitions to Chief Operating Officer, leading strategy execution and corporate functions.

 

Full-year Crop Protection sales reached $13.7 billion, up 4% (3% CER). “Overall volumes increased as channel inventory normalization materialized across key markets,” the company said. North America led regional growth with a 10% increase, while China posted 8% growth. Brazil and LATAM faced pricing pressures and currency effects.

 

Syngenta received over 1,800 approvals globally, including the EPA approval of PLINAZOLIN technology in the U.S., TYMIRIUM registrations in multiple markets, and the launch of ALTESSIA in India.

 

Seeds sales totaled $4.8 billion, up 2%. Field Crops sales were strong in Brazil (+17%) and LATAM (+10%), while North America declined 12% due to restructuring. Syngenta launched DURASTAK™ in North America and ENLIST E3 EXPANCE™ for soybeans, while vegetable seeds expanded through partnerships and AI-driven breeding technologies.

 

“Syngenta also expanded its global infrastructure, opening a state-of-the-art Seed Health Lab in the Netherlands and investing in Guatemala to accelerate innovation in fruity crops,” the company said.

 

Meanwhile, Syngenta China posted $8.3 billion in 2025 sales, down 10% primarily due to strategic grain trading reductions. Seeds and Branded Formulations grew 7% and 5%, respectively. Highlights included the completion of the Nantong crop protection plant and 122 new national variety approvals.

 

Effective December 31, 2025, Syngenta spun off Sinofert Holdings, removing the fertilizer business from consolidated results.

 

ADAMA sales totalled $4.1 billion, down 2%, though EBITDA and margins improved for the sixth consecutive quarter. North America grew 11%, while Asia Pacific (excluding China) declined 16% due to strategic commodity reductions. New products launched included CAZADO in Canada, TEMPER More in the US, FERALLA in the EU, and GILBOA for cereals.